NEW YORK--(BUSINESS WIRE)--Blink Health, America’s leading prescription drug savings platform, today announced the appointment of John J. Mack as Senior Advisor. The appointment follows the completion of the company’s $90 million Series B financing and the addition of Senator Kelly Ayotte as Senior Advisor.
“Working with innovative companies that use technology to solve important problems is a key focus for me,” said Mack. “I have always had a passion for healthcare and have seen first-hand how patient access to affordable medication drives better healthcare outcomes. Blink Health's technology is solving a systemic problem in this country -- high drug prices.”
Mack has had a distinguished, 40-year career building financial institutions and supporting America’s entrepreneurial businesses, having served as Chairman and CEO of Morgan Stanley and CEO of Credit Suisse First Boston. He is currently a trustee of New York-Presbyterian Hospital and the University Hospital of both Columbia and Cornell.
“We are thrilled to welcome John and fortunate to have the benefit of his experience as we expand our platform,” said Geoffrey Chaiken, CEO and Co-founder of Blink Health. “As one of the most well-regarded business leaders in America, John’s insights about business, technology and public policy will be an invaluable resource as we carry out our mission of making prescription drugs affordable for all Americans.”
Blink Health’s Senior Advisors constitute a small group of distinguished leaders who provide advice and counsel to Blink’s senior management and Board of Directors.
About Blink Health
Founded in 2014, Blink Health is a technology platform that enables consumers to access the medications they need at prices they can afford at over 57,000 pharmacies nationwide. Blink’s website and free mobile app allow users to purchase their medications online and pick them up at their local retailer for up to 90% off the average retail price. Blink Health groups patients together to leverage their purchasing power and secure significantly lower prices for the most-prescribed medications in America.